ings areavailable through the SEC website at http://www.sec.gov . Allforward-looking statements are based upon information available to Duska onthe date hereof. Duska undertakes no obligation to publicly update orrevise any forward-looking statements whether as a result of newinformation future events or otherwise other than as required by law.
Date:10/23/2008
ings are
available through the SEC website at
http://www.sec.gov. All
forward-looking statements are based upon information available to Duska on
the date hereof. Duska undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, other than as required by law.
'/>"/>SOURCE Duska Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado2.
CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team3.
ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)4.
Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service5.
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche6.
Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems7.
Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools8.
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic9.
iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits10.
Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV11.
Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies